Significant increases in the plasma expression of lncRNA-UCA1 [129], lncRNA16 [130], SPRY4-IT1, ANRIL, and NEAT1 [129] indicate the biomarker potential that these lncRNAs might prove to have in NSCLC patients. The gene discussed is CDKN2B-AS1; the disease is non-small cell lung carcinoma.